These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 9990361)
1. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Mrowietz U; Graeber M; Bräutigam M; Thurston M; Wagenaar A; Weidinger G; Christophers E Br J Dermatol; 1998 Dec; 139(6):992-6. PubMed ID: 9990361 [TBL] [Abstract][Full Text] [Related]
2. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Mrowietz U; Wustlich S; Hoexter G; Graeber M; Bräutigam M; Luger T Acta Derm Venereol; 2003; 83(5):351-3. PubMed ID: 14609102 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Van Leent EJ; Gräber M; Thurston M; Wagenaar A; Spuls PI; Bos JD Arch Dermatol; 1998 Jul; 134(7):805-9. PubMed ID: 9681343 [TBL] [Abstract][Full Text] [Related]
4. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Luger T; Van Leent EJ; Graeber M; Hedgecock S; Thurston M; Kandra A; Berth-Jones J; Bjerke J; Christophers E; Knop J; Knulst AC; Morren M; Morris A; Reitamo S; Roed-Petersen J; Schoepf E; Thestrup-Pedersen K; Van Der Valk PG; Bos JD Br J Dermatol; 2001 Apr; 144(4):788-94. PubMed ID: 11298538 [TBL] [Abstract][Full Text] [Related]
5. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007 [TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Angelo JS; Kar BR; Thomas J Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037 [TBL] [Abstract][Full Text] [Related]
9. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Grassberger M; Baumruker T; Enz A; Hiestand P; Hultsch T; Kalthoff F; Schuler W; Schulz M; Werner FJ; Winiski A; Wolff B; Zenke G Br J Dermatol; 1999 Aug; 141(2):264-73. PubMed ID: 10468798 [TBL] [Abstract][Full Text] [Related]
10. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Neckermann G; Bavandi A; Meingassner JG Br J Dermatol; 2000 Apr; 142(4):669-79. PubMed ID: 10792216 [TBL] [Abstract][Full Text] [Related]
11. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Meingassner JG; Grassberger M; Fahrngruber H; Moore HD; Schuurman H; Stütz A Br J Dermatol; 1997 Oct; 137(4):568-76. PubMed ID: 9390333 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial. Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049 [TBL] [Abstract][Full Text] [Related]
14. Clearing of psoriasis by a novel immunosuppressive macrolide. Rappersberger K; Meingassner JG; Fialla R; Födinger D; Sterniczky B; Rauch S; Putz E; Stütz A; Wolff K J Invest Dermatol; 1996 Apr; 106(4):701-10. PubMed ID: 8618008 [TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate for psoriasis: are ointments really more potent? Warino L; Balkrishnan R; Feldman SR J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104 [TBL] [Abstract][Full Text] [Related]
16. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Paul C; Graeber M; Stuetz A Expert Opin Investig Drugs; 2000 Jan; 9(1):69-77. PubMed ID: 11060661 [TBL] [Abstract][Full Text] [Related]
17. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Lebwohl M; Freeman AK; Chapman MS; Feldman SR; Hartle JE; Henning A; J Am Acad Dermatol; 2004 Nov; 51(5):723-30. PubMed ID: 15523350 [TBL] [Abstract][Full Text] [Related]
18. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Harper J; Green A; Scott G; Gruendl E; Dorobek B; Cardno M; Burtin P Br J Dermatol; 2001 Apr; 144(4):781-7. PubMed ID: 11298537 [TBL] [Abstract][Full Text] [Related]
19. Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A 4-week, randomized, double-blind clinical trial. Corrocher G; Di Lorenzo G; Mansueto P; Martinelli N; Esposito-Pellitteri M; Gelio S; Lombardo G; Pacor ML Clin Ther; 2006 Sep; 28(9):1296-302. PubMed ID: 17062302 [TBL] [Abstract][Full Text] [Related]
20. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Liao YH; Chiu HC; Tseng YS; Tsai TF Br J Dermatol; 2007 Nov; 157(5):1005-12. PubMed ID: 17935517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]